Non-Pharmac Cancer Drugs: What Your Health Policy Actually Pays
Pharmac decides which medicines the public system funds in New Zealand. A drug that is registered as safe and effective by Medsafe but not funded by Pharmac is available here, you simply pay for it yourself.
That is the gap health insurers price around, and it is the gap that ruins people. Modern cancer treatments that Pharmac has not funded routinely run to six figures over a course of treatment.
So the question is not whether your policy covers cancer. Nearly all of them do. It is how much of an unfunded drug bill it will pay, and that number is usually a sub-limit hiding inside a larger benefit.
Southern Cross Wellbeing
From the Wellbeing One and Two Policy document, effective 1 April 2026 (retrieved 8 September 2026):
Chemotherapy for cancer (base): $60,000 each claims year (includes $10,000 for chemotherapy drugs that are not Pharmac approved but Medsafe-indicated)
Read the bracket. The non-Pharmac portion is $10,000, and it is inside the $60,000, not on top of it. The drug must also be Medsafe-indicated for the specific cancer you have been diagnosed with, a drug used off-label for your cancer does not qualify.
$10,000 against a treatment course that can cost $100,000 or more is a contribution, not cover.
The upgrade that changes the answer
Southern Cross sells optional Cancer Cover Plus upgrades:
| Option | Chemotherapy limit |
|---|---|
| Base | $60,000 each claims year |
| Chemotherapy 100 | $100,000 each claims year |
| Chemotherapy 300 | $300,000 each claims year |
An excess applies to each. The upgrade replaces the base chemotherapy benefit rather than adding to it, and your membership certificate confirms which one you hold.
If unfunded cancer drugs are the risk that worries you, and for most people buying health insurance in their forties and fifties, it should be, Chemotherapy 300 is the specific thing to ask about. It is the difference between a policy that contributes to a cancer bill and one that covers it.
There is a catch worth knowing: the upgrade replaces the base benefit except where the exclusion for family history of cancer applies. If you have a family history, ask precisely how that exclusion interacts with the upgrade before you rely on it.
Accuro and UniMed SmartCare
Accuro, now UniMed, splits the two tiers on exactly this point.
SmartCare+ covers non-Pharmac drugs. SmartCare does not.
SmartCare's private hospital medical admission benefit is $200,000 a policy year, with chemotherapy and radiation capped at $65,000 inside it. SmartCare+ raises the admission benefit to $300,000 without that inner cap, and adds non-Pharmac drug cover.
That is the clearest tier split in the New Zealand market, and it is almost entirely a cancer decision. Everything else separating the two plans is marginal by comparison.
Why the sub-limit is the number that matters
Health insurance is sold on headline limits. A plan advertising $300,000 or $500,000 of surgical cover sounds comprehensive, and for surgery it is.
Cancer does not work that way. The expensive part of a modern cancer year is often not the operation, it is the drugs, and the drugs sit under a separate benefit with its own, much smaller, ceiling.
So when QuoteHub compares policies on cancer cover, the order of importance is:
- The non-Pharmac drug sub-limit, in dollars
- The total chemotherapy benefit it sits inside
- Whether an upgrade exists, and what it costs
- Everything else
Comparing surgical limits between two plans while ignoring their non-Pharmac positions is comparing the wrong thing carefully.
Two conditions that catch people
Medsafe indication. Cover generally requires the drug to be Medsafe-indicated for the cancer you have. Oncologists sometimes prescribe a drug that is Medsafe-registered for one cancer to treat a different one, where evidence supports it. That prescription is legitimate medicine and may not be a covered claim. Ask your insurer in writing before treatment starts, not after.
Affiliated Provider requirements. Southern Cross requires chemotherapy to be performed by an Affiliated Provider contracted for chemotherapy treatment. Treatment delivered outside that network may not be covered at all, regardless of the limits. Where you are treated can matter as much as what you are treated with.
What we are not going to tell you
We are not going to publish a table of "typical" unfunded cancer drug costs. Prices vary by drug, by dose, by duration and by supplier, and a plausible-looking average would be invented rather than sourced. If you want a real figure for a real drug, your oncologist or the supplier can give you one for your situation.
Nor are we going to rank insurers on this. The right answer depends on your age, your family history, your budget and what a change would do to your pre-existing condition position, which is the thing most likely to cost you money if you switch. That is covered in health insurance and pre-existing conditions.
The one thing to do
Find your current policy document and search it for "Pharmac". Whatever number appears next to it is your real cancer drug cover, and most people who hold health insurance have never looked at it.
If that number is $10,000 and you are in your fifties, the upgrade conversation is worth having this year rather than after a diagnosis, because a diagnosis closes the door on changing anything.
Financial advice on this site is provided by Craig Smith Business Services Limited, trading as Smiths Insurance & KiwiSaver, a licensed Financial Advice Provider (FSP712931).
Read the full insurance guides
Compare your cover with a licensed NZ adviser · free, no obligation.
Explore related pages: Life Insurance, Income Protection, Health Insurance, Trauma Insurance, What You Get.